ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a joint stock company founded in the Zhangjiang High Tech Park, China (Shanghai) Pilot Free Trade Zone in June, 2015. We are a science-driven biotechnology company dedicated to the development of next-generation immuno-oncology therapies. We stand out as one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Currently approved immunotherapies primarily focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address significant unmet medical needs of cancer patients. We have 7 ongoing clinical programs since our company inception.